SynthesisBMC ophthalmology2025
Intravitreal anti-vascular endothelial growth factor agents as an adjunct for proliferative diabetic retinopathy: a systematic review and meta-analysis.
Synthesis in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of different anti-VEGF agents combined with pars plana vitrectomy in proliferative diabetic retinopathy: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- Sequential Surgical Management of Refractory Primary Angle-Closure Glaucoma in a Functionally Monocular Patient.Life (Basel, Switzerland) · 2026Article
- Perioperative anti-vascular endothelial growth factor treatment in diabetic vitrectomy: A narrative review.Indian journal of ophthalmology · 2026Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents adjunct prior to pars plana vitrectomy (PPV) for patients with proliferative diabetic retinopathy (PDR).
methodsA systematically comprehensive literature search was performed in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang, VIP Database for Chinese Technical Periodicals, and Chinese Biomedical Literature Database to identify relevant randomized controlled trials (RCTs) up to October 31, 2024. The Peferred Reporting Items for Systematic Reviews and Meta Analysis guidelines were followed. Review Manager 5.4 software was used to conduct statistical analyses.
results91 RCTs involving 8721 eyes were included. The intraoperative indices revealed that the amount, grade and incidence of intraoperative bleeding, duration of surgery, the frequency of endodiathermy, the incidences of iatrogenic retinal breaks, endodiathermy, retinotomy, and silicone oil tamponade were significantly less in the PPV + anti-VEGF group than in the PPV group (P < 0.05). Moreover, the postoperative indices showed that anti-VEGF agents adjunct before PPV could achieve better postoperative best corrected visual acuity (BCVA) at different time points, higher postoperative retinal anatomical reattachment, lower postoperative macular retinal thickness (MRT) at different time points and intraocular pressure (IOP) at < 1 month, ≥ 3 months but < 6 months, and shorter clearing time of postoperative vitreous hemorrhage (POVH) (P < 0.05). Furthermore, the incidences of postoperative complications such as early POVH, late POVH at different time points, retinal detachment, re-proliferation, aseptic and infective endophthalmitis, iris rubeosis, neovascular glaucoma, hyphema, and elevated IOP were significantly lower in the PPV + anti-VEGF group than in the PPV group (P < 0.05). Besides, anti-VEGF agents adjunct before PPV could achieve lower re-PPV probability (P < 0.0001).
conclusionsIntravitreal anti-VEGF agents adjunct prior to PPV for PDR patients might facilitate much easier surgery, shorter surgical time, better postoperative BCVA, and lower postoperative MRT; meanwhile reduce the incidence of intraoperative and postoperative complications, and the risk of re-PPV. In addition, more RCTs with better design, larger sample sizes and longer follow-up time are needed to provide more reliable evidence. PROSPERO REGISTRATION NUMBER: CRD42024604615 (22 October 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.